earnings
confidence high
sentiment negative
materiality 0.65
AbbVie lowers Q2 and FY 2026 adjusted EPS guidance by $0.17 on $291M IPR&D expense
AbbVie Inc.
- Q2 2026 adjusted diluted EPS guidance reduced to $3.57-$3.61 from $3.74-$3.78.
- Full-year 2026 adjusted diluted EPS guidance reduced to $13.91-$14.11 from $14.08-$14.28.
- $291M pre-tax acquired IPR&D and milestones expense incurred in Q2 2026.
- Expense relates to collaborations, licensing, and asset acquisitions; not previously forecasted.